DegenRx is a biotechnology company focused on developing innovative AAV-mediated gene therapies aimed at treating central nervous system (CNS) diseases, particularly Alzheimer’s and Parkinson’s disease. The company utilizes Adeno-Associated Viral (AAV) vectors to deliver therapeutic genes directly into the brain, which facilitates the local production of therapeutic antibodies. This approach is designed to provide a highly efficient treatment with a single administration, ensuring that the therapeutic effects are sustained over an extended period while minimizing exposure to the rest of the body.

The gene therapy technology employed by DegenRx leverages the unique properties of AAVs, which are modified to carry beneficial genetic material without integrating into the host's genetic material. This characteristic makes AAVs particularly suitable for targeting non-dividing cells, such as neurons, and allows for the effective delivery of therapeutic proteins. The company’s collaboration with the Center for Neurogenomics & Cognitive Research (CNCR) has been bolstered by a grant aimed at advancing research in antibody-based gene therapy for Alzheimer’s disease, highlighting the potential of this innovative approach to overcome significant challenges in drug delivery, such as the blood-brain barrier.

Netherlands

DegenRx is a biotech company developing AAV-mediated gene therapy for the treatment of Alzheimer’s disease. Using Adeno-Associated-Viral (AAV) vectors we deliver genes in the brain that initiate the local production of therapeutic antibodies

DegenRx

Company Details